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Abstract Variable number tandem repeats (VNTR) within non-
coding regions of a number of genes have been correlated with
susceptibility to various disease states. In particular, a VNTR
polymorphism of a 16 or 17 bp element within intron 2 of the
human serotonin transporter gene has been correlated with a
predisposition to affective disorders. We have demonstrated that
this region will support differential levels of reporter gene
expression in differentiating embryonic stem cells, this being
dependent on the presence of 10 or 12 copies of the repeat. The
VNTR domain can therefore act as a transcriptional regulator, a
property which potentially contributes to disease susceptibility.
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1. Introduction
Genetic factors have been implicated in the aaetiology of
mental illness but identi¢cation of the gene(s) involved is very
di⁄cult because of the complex inheritance patterns of these
disorders. Clinical abnormalities in monoamine metabolism,
in particular serotonin (5-HT) and dopamine have been im-
plicated in the pathophysiology of many CNS related disor-
ders and the use of drugs that block the e¡ects of the seroto-
nin transporter (5-HTT) and the dopamine transporter
(DAT1) have pointed to these being candidate genes involved
in behavioural or mental disturbances [1,2]. Both 5-HTT and
DAT1 genes contain polymorphic regions termed variable
number tandem repeats (VNTRs) within non-coding regions
but the role of these VNTRs is at present highly debatable [3^
12].
A VNTR polymorphism within intron 2 of the human 5-
HTT gene (STin2) comprises between 9 and 12 copies of a 16
or 17 base pair length element (Figure 1a), the number of
repeat elements having been correlated with a predisposition
to a¡ective disorders and anxiety symptoms [3^5,13,14]. Be-
cause of the location of this polymorphism and the size of the
individual repeat elements, we postulated that this domain
might act as a transcriptional regulator.
A small number of publications have indicated that VNTRs
representing susceptibility factors for various disorders or dis-
eases can act as transcriptional regulators. These include a 5P
VNTR within the 5-HTT promoter and also the IDDM2
locus that encodes susceptibility to human type 1 diabetes
[15]. In order to de¢ne the potential regulatory properties of
the STin2 VNTR we therefore proposed to determine whether
it could support reporter gene expression in cell line models
and, if so, would the VNTR support di¡erential reporter gene
expression based on the copy number of the repeat. The latter
would potentially correlate with predisposition to a¡ective
disorders by modulating expression of 5-HTT or an adjacent
gene at this locus.
2. Materials and methods
2.1. Construction of reporter gene constructs
Genomic DNA from 9-copy (Stin2.9), 10-copy (STin2.10) and 12-
copy (STin2.12) VNTR individuals was ampli¢ed by PCR using








(Figure 1a) of Battersby et al. [3]. Nucleotide numbering commences
at the start of exon 1 and is consistent with the presence of STin2.12.
PCR products were cloned into the pGL3 promoter vector (pGL3p,
Promega) upstream of the SV40 promoter. A number of clones of
each construct were sequenced in both directions to con¢rm the num-
ber of repeats, orientation and exact nucleotide sequence.
2.2. Growth and transfection of cells
Embryonic Stem (ES) cells, HM-1, were cultured as per Magin et
al. [16] in the presence of LIF. Cells at 70^80% con£uence in 24 well
plates were transfected in triplicate with 1Wg pGL3p vector or speci¢c
5-HTT VNTR pGL3p construct using Lipofectin (Life Technologies)
and following the manufacturer’s directions. Cells were then trans-
ferred to speci¢c medium +/3 LIF and +/3 retinoic acid (RA) for
64h (optimal for ES cells).
HeLa cells were cultured under standard conditions. 2U105 cells
were incubated for 16h in medium containing 0.5% serum, transfected
by electroporation with 5 to 20 Wg DNA using the Equibio EasyJect
at the optimal 250V and capacitance of 1500mF then incubated in
complete medium for 48h (optimal for HeLa).
2.3. Analysis of reporter gene expression
Cells were washed with PBS, lysed with 250 Wl Promega lysis bu¡er
and supernatants assayed for luciferase activity using the Promega
assay reagent and Life Sciences Labsystems Luminoskan RT. Results
are quoted as expressed luciferase from each construct relative to
baseline pGL3p expression (Relative Luciferase Expression).
3. Results
3.1. STin2 VNTR sequences
Stin2.9, STin2.10 and STin2.12 PCR products were cloned
into the vector pGL3p and a number of clones of each se-
quenced. The 12-copy VNTR repeat elements have been num-
bered in two ways in Figure 1b in order to de¢ne both the
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position of the element within the VNTR and it’s individual
sequence, ie. RP1 to RP12 identify the position and lower case
letters, a-g, identify the sequence of each unique repeat ele-
ment. Di¡erences between these elements are only seen at
speci¢c positions ie. residues 6, 10, 11, 12, 14 and 15. In
addition, only C/T and G/A substitutions are seen. Relative
to STin2.12, STin2.10 is missing d and g element sequences
which comprise RP9 and RP10. Repeated attempts to clone
the 9-copy STin2.9 VNTR produced unstable constructs
which were therefore not suitable for use in the current trans-
fection experiments.
3.2. Embryonic stem cells, but not HeLa cells, support
di¡erential levels of reporter gene expression from the
10- and 12-copy STin2 VNTRs
The potential for the two VNTRs to support reporter gene
expression was assessed by transfecting luciferase expression
constructs containing STin2.10 and STin2.12 in triplicate into
ES cells, which were subsequently incubated in the presence or
absence of LIF, and into HeLa cells. Data from duplicate ES
cell transfection experiments is presented in Figure 2 as lucif-
erase expression relative to that from the pGL3p vector. Re-
porter gene expression was dramatically di¡erent depending
on whether or not LIF was present in the growth medium
post transfection. In the presence of LIF, STin2.10 showed
some reduction in reporter gene expression (relative expres-
sion = 0.31 þ 0.02) and STin2.12 had no signi¢cant e¡ect (rel-
ative expression = 1.14 þ 0.15). Withdrawal of LIF however,
resulted in dramatically increased expression from both con-
structs. ie. STin2.10 increased the relative expression by 5.77
( þ 1.54) fold and STin2.12 by 167.85( þ 10.35) fold over
pGL3p. In contrast to ES cells, neither VNTR exhibited
any in£uence on reporter gene expression in HeLa cells
(data not shown).
Retinoic acid (RA) is used as a morphogen in the di¡er-
entiation of ES cells [17]. RA, added at 10^500nM to both
LIF+ and LIF3 media post transfection, was capable of
modulating reporter gene expression from our VNTR con-
tructs both with and without LIF in the medium, Figure 3a,
although LIF3 e¡ects were more dramatic than LIF+. The
enhanced expression which was seen after withdrawal of LIF
was progressively reduced by increasing concentrations of
RA, STin2.12 expression being reduced by up to 60% and
STin2.10 by up to 16% by 500nM RA.
4. Discussion
A genetic basis for the progression of, or predisposition to,
a¡ective disorders and other behaviour related traits is likely
to be multifactorial. Although polymorphic regions composed
of VNTRs are often associated with predisposition to a par-
ticular disease, these genetic markers have generally been used
to predict individuals at risk and few attempts have been
made to determine the mechanisms behind this correlation.
The size of the individual repeat elements within the recently
described STin2 VNTR polymorphism suggests potential for
binding transcription factors which would implicate the
VNTR as a transcriptional regulator of gene expression at
this locus.
Our transient transfection studies have shown that the
STin2 VNTRs can indeed act as transcriptional regulators
Fig. 1. Genomic location and sequence of the STin2 VNTR. The lo-
cation of the intronic VNTR within intron 2 of 5-HTT [30] is
shown with the consensus repeat element sequence indicated (Y = T/
C, R = A/G). Pr1 and Pr2 were used to PCR the VNTR region. b)
The STin2.12 VNTR sequence showing repeats RP1 through RP12.
Unique elements are delineated ‘a’ to ‘g’. Repeats RP9 and RP10
(bracketed) are not present in the STin2.10 VNTR.
Fig. 2. ES cells support di¡erential STin2.10 and STin2.12 reporter
gene expression. Transfected ES cells were incubated for 64h in me-
dium þ LIF. Reporter gene expression from triplicate STin2.10 and
STin2.12 transfections is presented as luciferase expression relative
to baseline pGL3p. Data represents the combined results of two ex-
periments.
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and that activity can be cell-speci¢c. ES cells are pluripotent
cells derived from the inner cell mass of blastocysts. Culturing
ES cells in the presence of LIF allows them to be maintained
in an undi¡erentiated state for many passages in culture [18].
In this state ES cells do not support enhancer activity by
either VNTR construct and STin2.10 appears to reduce ex-
pression from the SV40 minimal promoter to some extent.
Withdrawal of LIF is su⁄cient to induce di¡erentiation of
ES cells into endoderm-like cells and morphologically distin-
guishable cell populations normally appear over a period of
days [19]. Changes at the molecular level can however be seen
as early as 36hrs after LIF withdrawal and these appear to be
su⁄cient to permit enhancer activity of the STin2 VNTR
domains when in the context of an SV40 minimal promoter-
driven reporter gene construct. In contrast to results obtained
from ES cells, no response to the presence of either VNTR in
the constructs could be detected in HeLa cells. Although LIF-
and LIF+ ES cells support such di¡erent levels of reporter
gene expression, preliminary electrophoretic mobility shift
analyses (EMSA) using oligonucleotides representing unique
repeat elements have not shown any obvious correlation be-
tween novel factor binding and the activation described
above. HeLa cell extracts on the other hand do appear to
form far fewer complexes than ES cells. The mechanisms in-
volved in transcriptional control by VNTRs are likely to be
complex and the relationship between activation, or lack of,
and the observed complexes is under investigation.
Under the conditions used in this study, STin2.12 acted as a
signi¢cantly stronger enhancer than STin2.10 in di¡erentiating
ES cells. Although it appears that the presence of the two
additional repeat elements is enough to increase the enhancer
potential of the VNTR, the presence of a number of distinct
elements within the VNTRs highlights the potential for var-
iations within the VNTR, as distinct from just copy number.
Repeated motifs can be identi¢ed within the VNTR which
resemble known transcription factor binding sites. Transient
transfection data leads us to believe that the VNTR contains
both positive and negative regulatory motifs.
In the context of the whole 5-HTT promoter, the VNTR
may a¡ect both distribution and rate of transcription. It has
in fact now been demonstrated that both STin2 VNTRs ex-
hibit highly restrictive patterns of expression in transgenic
mouse embryos when in the context of a reporter gene con-
struct under the control of the L-globin minimal promoter.
[MacKenzie et al., submitted]. Expression of the marker
gene in embryos transgenic for either of the constructs was
consistent except within the rostral hindbrain where STin2.12
drove higher expression of the marker gene than STin2.10.
This observation is in agreement with our ES cell transfection
data which also shows STin2.12 to be the stronger regulator.
Interestingly, the rostral hindbrain has been shown to express
5-HTT mRNA [20] and is associated with the development of
rostral serotonergic neuronal clusters [21]. Our observation
that RA can modulate the activity of the STin2 VNTR con-
structs is therefore interesting because the developing embry-
onic nervous system is also known to be sensitive to RA [22].
In vitro, the combined e¡ects of removal of LIF and addition
of RA can induce ES cells to di¡erentiate into neuron-like
cells through some as yet unknown mechanism [23]. Although
potential retinoic acid response element motifs [24] are found




immediately 5P of the





the middle of a number of the repeats, we have no evidence
for direct RA interaction with the VNTR.
As the STin2 VNTR region is correlated with a predispo-
sition to a¡ective disorders, understanding the regulatory role
of the VNTR will have direct clinical relevance to our under-
standing of the aaetiology of the disorders and suggest novel
strategies for the treatment of these conditions via manipula-
tion of 5-HTT gene expression. More generally it demon-
strates that polymorphic regions, previously only used as ge-
netic markers, may have a function in regulating speci¢c gene
expression. We view the STin2 VNTR as distinct from the
trinucleotide repeats, such as the CAG/CTG elements previ-
ously associated with schizophrenia which, although having
variable copy number, are unlikely to have su⁄cient sequence
information in each repeat to specify a sequence-speci¢c tran-
scription factor binding site. A precedent for VNTRs to act as
transcriptional enhancers has been demonstrated within other
genes, e.g the 5P promoter polymorphism in the 5-HTT gene
itself [25] and a locus within the IDDM2 gene [15,26^28]. Our
results suggest that many previously identi¢ed polymorphic
VNTR regions with known disease associations and in which
the repeat elements are of su⁄cient length to contain tran-
scription factor binding motifs, should be re-evaluated to de-
termine whether they could act as transcriptional regulators.
In conclusion, we have shown that the Serotonin transport-
er intron 2 VNTR can act as a transcriptional regulator with
potential for de¢ning cell-speci¢c di¡erential gene expression.
The mechanism whereby Stin2.10 and Stin2.12 exert distinct
Fig. 3. E¡ect of retinoic acid on STin2 VNTR reporter gene expres-
sion in ES cells. Transfected ES cells were incubated þ LIFand plus
RA at 0, 10, 100 or 500nM. Results are presented as relative lucifer-
ase expression from triplicate transfections. LIF+ data is shown as
an insert within the LIF3 ¢gure.
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e¡ects is unclear, however, as seen in ¢gure 1, individual re-
peat elements show sequence variations. In principle, one or
two nucleotide changes in a consensus sequence can either
specify for a speci¢c transcription factor complex or can alter
binding a⁄nity [29]. It is conceivable therefore that both the
number of repeats comprising the VNTR and the sequence of
individual elements within it are likely to be major determi-
nants of VNTR activity. The relative importance of each el-
ement within the VNTR is currently being analysed and the
functional signi¢cance is being determined both in vitro and
by transgenic analysis in vivo.
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